|
AstraZeneca PLC on Monday said that Imfinzi plus Imjudo showed a clinically meaningful overall survival benefit for patients with a form of liver cancer. The Cambridge-based pharmaceutical company said the benefit was for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localised treatment. AstraZeneca said the results from the phase 3 Himalaya study will be presented today at the European Society for Medical Oncology Congress in Barcelona. AstraZeneca said that about 20% of patients treated with the Stride regimen, which is a single dose of Imjudo added to Imfinzi, were alive at five years, compared to 9.4% of those treated with sorafenib, a drug used to treat some types of cancer. The company highlighted that in the subgroup analysis of patients in the trial who achieved disease control, about 29% of those treated with the Stride regimen were alive at five years compared to around 13% of patients treated with sorafenib. Susan Galbraith, executive vice president, Oncology research & development at AstraZeneca, said: ‘It is remarkable to see nearly 20 per cent of patients with advanced liver cancer treated with the Stride regimen alive at five years compared to only about seven per cent of patients living that long historically. This is a major step forward, setting a new survival benchmark.’ AstraZeneca shares were 0.6% higher at 11,997.64 pence each on Monday morning in London. Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
